Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 409

1.

Postoperative prophylactic antibiotics for facial fractures: A systematic review and meta-analysis.

Habib AM, Wong AD, Schreiner GC, Satti KF, Riblet NB, Johnson HA, Ossoff JP.

Laryngoscope. 2018 May 14. doi: 10.1002/lary.27210. [Epub ahead of print] Review.

PMID:
29756330
2.

A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints.

Moreno-Ulloa A, Nájera-García N, Hernández M, Ramírez-Sánchez I, Taub PR, Su Y, Beltrán-Partida E, Ceballos G, Dugar S, Schreiner G, Best BM, Ciaraldi TP, Henry RR, Villarreal F.

Food Funct. 2018 Jan 24;9(1):307-319. doi: 10.1039/c7fo01028a.

PMID:
29171848
3.

A randomized, placebo-controlled, double-blind study on the effects of (-)-epicatechin on the triglyceride/HDLc ratio and cardiometabolic profile of subjects with hypertriglyceridemia: Unique in vitro effects.

Gutiérrez-Salmeán G, Meaney E, Lanaspa MA, Cicerchi C, Johnson RJ, Dugar S, Taub P, Ramírez-Sánchez I, Villarreal F, Schreiner G, Ceballos G.

Int J Cardiol. 2016 Nov 15;223:500-506. doi: 10.1016/j.ijcard.2016.08.158. Epub 2016 Aug 8.

PMID:
27552564
4.

Pharmacokinetic, partial pharmacodynamic and initial safety analysis of (-)-epicatechin in healthy volunteers.

Barnett CF, Moreno-Ulloa A, Shiva S, Ramirez-Sanchez I, Taub PR, Su Y, Ceballos G, Dugar S, Schreiner G, Villarreal F.

Food Funct. 2015 Mar;6(3):824-33. doi: 10.1039/c4fo00596a.

5.

Proteomic biomarkers of recovered heart function.

Hollander Z, Lazárová M, Lam KK, Ignaszewski A, Oudit GY, Dyck JR, Schreiner G, Pauwels J, Chen V, Cohen Freue GV, Ng RT, Wilson-McManus JE, Balshaw R, Tebbutt SJ, McMaster RW, Keown PA, McManus BM; NCE CECR PROOF Prevention of Organ Failure (PROOF) Centre of Excellence.

Eur J Heart Fail. 2014 May;16(5):551-9. doi: 10.1002/ejhf.65. Epub 2014 Feb 23.

6.

Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver.

Lanaspa MA, Sanchez-Lozada LG, Cicerchi C, Li N, Roncal-Jimenez CA, Ishimoto T, Le M, Garcia GE, Thomas JB, Rivard CJ, Andres-Hernando A, Hunter B, Schreiner G, Rodriguez-Iturbe B, Sautin YY, Johnson RJ.

PLoS One. 2012;7(10):e47948. doi: 10.1371/journal.pone.0047948. Epub 2012 Oct 24.

7.

Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver.

Lanaspa MA, Sanchez-Lozada LG, Choi YJ, Cicerchi C, Kanbay M, Roncal-Jimenez CA, Ishimoto T, Li N, Marek G, Duranay M, Schreiner G, Rodriguez-Iturbe B, Nakagawa T, Kang DH, Sautin YY, Johnson RJ.

J Biol Chem. 2012 Nov 23;287(48):40732-44. doi: 10.1074/jbc.M112.399899. Epub 2012 Oct 3.

8.

Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy.

Tanabe K, Tamura Y, Lanaspa MA, Miyazaki M, Suzuki N, Sato W, Maeshima Y, Schreiner GF, Villarreal FJ, Johnson RJ, Nakagawa T.

Am J Physiol Renal Physiol. 2012 Nov 1;303(9):F1264-74. doi: 10.1152/ajprenal.00227.2012. Epub 2012 Aug 29.

9.

Nicorandil, a K(atp) channel opener, alleviates chronic renal injury by targeting podocytes and macrophages.

Tamura Y, Tanabe K, Kitagawa W, Uchida S, Schreiner GF, Johnson RJ, Nakagawa T.

Am J Physiol Renal Physiol. 2012 Aug 1;303(3):F339-49. doi: 10.1152/ajprenal.00158.2012. Epub 2012 May 23.

10.

Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse.

Tanabe K, Lanaspa MA, Kitagawa W, Rivard CJ, Miyazaki M, Klawitter J, Schreiner GF, Saleem MA, Mathieson PW, Makino H, Johnson RJ, Nakagawa T.

Am J Physiol Renal Physiol. 2012 May 1;302(9):F1151-60. doi: 10.1152/ajprenal.00596.2011. Epub 2012 Feb 15.

11.

Comparison of hospital risk-standardized mortality rates calculated by using in-hospital and 30-day models: an observational study with implications for hospital profiling.

Drye EE, Normand SL, Wang Y, Ross JS, Schreiner GC, Han L, Rapp M, Krumholz HM.

Ann Intern Med. 2012 Jan 3;156(1 Pt 1):19-26. doi: 10.7326/0003-4819-156-1-201201030-00004. Erratum in: Ann Intern Med. 2012 Mar 6;156(5):404.

12.

Hospital volume and 30-day mortality for three common medical conditions.

Ross JS, Normand SL, Wang Y, Ko DT, Chen J, Drye EE, Keenan PS, Lichtman JH, Bueno H, Schreiner GC, Krumholz HM.

N Engl J Med. 2010 Mar 25;362(12):1110-8. doi: 10.1056/NEJMsa0907130.

13.

Recent declines in hospitalizations for acute myocardial infarction for Medicare fee-for-service beneficiaries: progress and continuing challenges.

Chen J, Normand SL, Wang Y, Drye EE, Schreiner GC, Krumholz HM.

Circulation. 2010 Mar 23;121(11):1322-8. doi: 10.1161/CIRCULATIONAHA.109.862094. Epub 2010 Mar 8.

PMID:
20212281
14.

Differences in patient survival after acute myocardial infarction by hospital capability of performing percutaneous coronary intervention: implications for regionalization.

Chen J, Krumholz HM, Wang Y, Curtis JP, Rathore SS, Ross JS, Normand SL, Schreiner GC, Mulvey G, Nallamothu BK.

Arch Intern Med. 2010 Mar 8;170(5):433-9. doi: 10.1001/archinternmed.2009.538.

15.

The relationship between systolic blood pressure on admission and mortality in older patients with heart failure.

Vidán MT, Bueno H, Wang Y, Schreiner G, Ross JS, Chen J, Krumholz HM.

Eur J Heart Fail. 2010 Feb;12(2):148-55. doi: 10.1093/eurjhf/hfp195.

16.

Statistical models and patient predictors of readmission for acute myocardial infarction: a systematic review.

Desai MM, Stauffer BD, Feringa HH, Schreiner GC.

Circ Cardiovasc Qual Outcomes. 2009 Sep;2(5):500-7. doi: 10.1161/CIRCOUTCOMES.108.832949. Review.

PMID:
20031883
17.

Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission.

Krumholz HM, Merrill AR, Schone EM, Schreiner GC, Chen J, Bradley EH, Wang Y, Wang Y, Lin Z, Straube BM, Rapp MT, Normand SL, Drye EE.

Circ Cardiovasc Qual Outcomes. 2009 Sep;2(5):407-13. doi: 10.1161/CIRCOUTCOMES.109.883256. Epub 2009 Jul 9.

PMID:
20031870
18.

Recent national trends in readmission rates after heart failure hospitalization.

Ross JS, Chen J, Lin Z, Bueno H, Curtis JP, Keenan PS, Normand SL, Schreiner G, Spertus JA, Vidán MT, Wang Y, Wang Y, Krumholz HM.

Circ Heart Fail. 2010 Jan;3(1):97-103. doi: 10.1161/CIRCHEARTFAILURE.109.885210. Epub 2009 Nov 10.

19.

All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients.

Curtis JP, Schreiner G, Wang Y, Chen J, Spertus JA, Rumsfeld JS, Brindis RG, Krumholz HM.

J Am Coll Cardiol. 2009 Sep 1;54(10):903-7. doi: 10.1016/j.jacc.2009.04.076.

20.

Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.

Medicherla S, Li L, Ma JY, Kapoun AM, Gaspar NJ, Liu YW, Mangadu R, O'Young G, Protter AA, Schreiner GF, Wong DH, Higgins LS.

Anticancer Res. 2007 Nov-Dec;27(6B):4149-57. Erratum in: Anticancer Res. 2008 Jan-Feb;28(1b):567, 4152-3.

21.

Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed.

Schreiner GC, Laine L, Murphy SA, Cannon CP.

Crit Pathw Cardiol. 2007 Dec;6(4):169-72.

PMID:
18091407
22.

Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia.

Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, Lam A, O'Young G, Sannajust F, Stathis P, Schreiner G, Karumanchi SA, Protter AA, Pollitt NS.

Hypertension. 2007 Oct;50(4):686-92. Epub 2007 Aug 27.

PMID:
17724276
23.

Evidence for functional heterogeneity of circulating B-type natriuretic peptide.

Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, Apple FS, Maisel AS, Pollitt NS, Protter AA.

J Am Coll Cardiol. 2007 Mar 13;49(10):1071-8. Epub 2007 Feb 26.

24.

Improvement of human islet cryopreservation by a p38 MAPK inhibitor.

Omori K, Valiente L, Orr C, Rawson J, Ferreri K, Todorov I, Al-Abdullah IH, Medicherla S, Potter AA, Schreiner GF, Kandeel F, Mullen Y.

Am J Transplant. 2007 May;7(5):1224-32. Epub 2007 Feb 27.

25.

Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo.

Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, Schreiner G, Barnard N, Reiss M.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4315-30.

26.

Vascular endothelial growth factor administration does not improve microvascular disease in the salt-dependent phase of post-angiotensin II hypertension.

Long DA, Mu W, Price KL, Roncal C, Schreiner GF, Woolf AS, Johnson RJ.

Am J Physiol Renal Physiol. 2006 Dec;291(6):F1248-54. Epub 2006 Jun 27.

27.

Selective inhibition of p38alpha MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury.

Li Z, Ma JY, Kerr I, Chakravarty S, Dugar S, Schreiner G, Protter AA.

Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1972-7. Epub 2006 Jun 2.

28.

Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.

Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS.

Leukemia. 2006 Jun;20(6):1017-27.

PMID:
16617327
29.

Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes.

Medicherla S, Protter AA, Ma JY, Mangadu R, Almirez R, Koppelman B, Kerr I, Navas TA, Movius F, Reddy M, Liu YW, Luedtke G, Perumattam J, Mavunkel B, Dugar S, Schreiner GF.

J Pharmacol Exp Ther. 2006 Jul;318(1):99-107. Epub 2006 Apr 7.

30.

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D, Damm D, Reddy M, Ma JY, Haghnazari E, Kapoun AM, Medicherla S, Protter A, Schreiner GF, Kurihara N, Anderson J, Roodman GD, Navas TA, Higgins LS.

Exp Cell Res. 2006 Jun 10;312(10):1909-23. Epub 2006 Apr 4.

PMID:
16600214
31.

Inhibition of p38 mitogen-activated protein kinase protects human islets from cryoinjury and improves the yield, viability, and quality of frozen-thawed islets.

Omori K, Valiente L, Orr C, Rawson J, Ferreri K, Todorov I, Medicherla S, Protter AA, Schreiner GF, Riggs AD, Kandeel F, Mullen Y.

Transplant Proc. 2005 Oct;37(8):3422-3.

PMID:
16298615
32.

Nesiritide--not verified.

Schreiner G.

N Engl J Med. 2005 Oct 6;353(14):1525-7; author reply 1525-7. No abstract available.

PMID:
16211709
33.

Affymetrix oligonucleotide analysis of gene expression in the injured heart.

Yanagawa B, Taylor L, Deisher TA, Ng R, Schreiner GF, Triche TJ, Yang D, McManus BM.

Methods Mol Med. 2005;112:305-20. Review.

PMID:
16010026
34.

Role of ERK1/2 and p38 mitogen-activated protein kinases in the regulation of thrombospondin-1 by TGF-beta1 in rat proximal tubular cells and mouse fibroblasts.

Nakagawa T, Lan HY, Glushakova O, Zhu HJ, Kang DH, Schreiner GF, Böttinger EP, Johnson RJ, Sautin YY.

J Am Soc Nephrol. 2005 Apr;16(4):899-904. Epub 2005 Feb 16.

35.

p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells.

Lim MY, Wang H, Kapoun AM, O'connell M, O'Young G, Brauer HA, Luedtke GR, Chakravarty S, Dugar S, Schreiner GS, Protter AA, Higgins LS.

J Mol Cell Cardiol. 2004 Dec;37(6):1111-4.

PMID:
15572041
36.

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.

Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC.

Oncogene. 2004 Nov 18;23(54):8766-76.

PMID:
15480425
37.

Decreasing the use of mechanical restraints and locked seclusion.

Schreiner GM, Crafton CG, Sevin JA.

Adm Policy Ment Health. 2004 Jul;31(6):449-63.

PMID:
15478875
38.

p38 alpha mitogen-activated protein kinase inhibition improves cardiac function and reduces myocardial damage in isoproterenol-induced acute myocardial injury in rats.

Li Z, Tran TT, Ma JY, O'Young G, Kapoun AM, Chakravarty S, Dugar S, Schreiner G, Protter AA.

J Cardiovasc Pharmacol. 2004 Oct;44(4):486-92.

PMID:
15454858
39.

TGF-beta induces proangiogenic and antiangiogenic factors via parallel but distinct Smad pathways.

Nakagawa T, Li JH, Garcia G, Mu W, Piek E, Böttinger EP, Chen Y, Zhu HJ, Kang DH, Schreiner GF, Lan HY, Johnson RJ.

Kidney Int. 2004 Aug;66(2):605-13.

40.

Differential regulation of VEGF by TGF-beta and hypoxia in rat proximal tubular cells.

Nakagawa T, Lan HY, Zhu HJ, Kang DH, Schreiner GF, Johnson RJ.

Am J Physiol Renal Physiol. 2004 Oct;287(4):F658-64. Epub 2004 Jun 8.

41.

Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling.

Ge R, Rajeev V, Subramanian G, Reiss KA, Liu D, Higgins L, Joly A, Dugar S, Chakravarty J, Henson M, McEnroe G, Schreiner G, Reiss M.

Biochem Pharmacol. 2004 Jul 1;68(1):41-50.

PMID:
15183116
42.

Increased oxidative stress following acute and chronic high altitude exposure.

Jefferson JA, Simoni J, Escudero E, Hurtado ME, Swenson ER, Wesson DE, Schreiner GF, Schoene RB, Johnson RJ, Hurtado A.

High Alt Med Biol. 2004 Spring;5(1):61-9.

PMID:
15072717
43.

The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis.

Stambe C, Atkins RC, Tesch GH, Masaki T, Schreiner GF, Nikolic-Paterson DJ.

J Am Soc Nephrol. 2004 Feb;15(2):370-9.

44.

Inhibition of p38 mitogen-activated protein kinase augments progression of remnant kidney model by activating the ERK pathway.

Ohashi R, Nakagawa T, Watanabe S, Kanellis J, Almirez RG, Schreiner GF, Johnson RJ.

Am J Pathol. 2004 Feb;164(2):477-85.

45.

B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation.

Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA.

Circ Res. 2004 Mar 5;94(4):453-61. Epub 2004 Jan 15.

PMID:
14726474
46.

The birth of our logo.

Schreiner GE.

ASAIO J. 2003 Nov-Dec;49(6):633-4. No abstract available.

PMID:
14655725
47.

Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue.

Mavunkel BJ, Chakravarty S, Perumattam JJ, Luedtke GR, Liang X, Lim D, Xu YJ, Laney M, Liu DY, Schreiner GF, Lewicki JA, Dugar S.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):3087-90.

PMID:
12941340
48.

A single pathway for the development of essential hypertension.

Kanellis J, Nakagawa T, Herrera-Acosta J, Schreiner GF, Rodríguez-Iturbe B, Johnson RJ.

Cardiol Rev. 2003 Jul-Aug;11(4):180-96. Review. No abstract available.

PMID:
12852795
49.

Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue.

Lu E, Wagner WR, Schellenberger U, Abraham JA, Klibanov AL, Woulfe SR, Csikari MM, Fischer D, Schreiner GF, Brandenburger GH, Villanueva FS.

Circulation. 2003 Jul 8;108(1):97-103. Epub 2003 Jun 23.

PMID:
12821549
50.

Who put the tank in the tiger?

Schreiner GE.

ASAIO J. 2003 Jan-Feb;49(1):20-3. No abstract available.

PMID:
12558302

Supplemental Content

Loading ...
Support Center